Approvals & Mergers: Inside Enzyvant with Bill Symonds, Pharm.D.
Business Of Biotech
00:00
The Decision to Build a Regenerative Manufacturing Facility
There's about 20 children are 24 a year born in the US with congenital Ithymia. So it's a very low volume product, and it's also a highly bespoke manufacturing process where one donated thymus tissue treats one patient. The bigger part of the facility is actually all the supporting infrastructure to support the one room that's going to be making rithymics.
Transcript
Play full episode
